Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CB-5339 by CASI Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
CB-5339 is under clinical development by CASI Pharmaceuticals and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
CB-5339 by CASI Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
CB-5339 is under clinical development by CASI Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
CB-5339 by CASI Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
CB-5339 is under clinical development by CASI Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...